Background/Aims: We previously identified a potent and tight-binding inhibitor of cysteine proteases from Rhipicephalus haemaphysaloides, RHcyst-1, which belongs to the cystatin type 1 family. Cathepsins, which are members of the cysteine protease family, participate in various pathological processes, including the initiation and development of cancers. The present study aimed to investigate the antitumor effects of RHcyst-1 and to explore the underlying mechanism of these effects. Methods: Different tumor cells were treated with RHcyst-1 in vitro. Proliferation activity was evaluated using Cell Counting Kit-8, and migration and invasion were determined by wound healing and Transwell® invasion assays. In addition, a mouse tumor therapy model was established by inoculating the left forelimb of mice with B16-F10 cells, and tumor progression was evaluated by assessing tumor volume and survival. Flow cytometry was conducted to evaluate myeloid-derived suppressor cells (MDSCs), CD4 + , and CD8 + T cell levels in PBMCs and spleens. Immunohistochemistry was performed to analyze immune cell infiltration and angiogenesis in the tumors. Results: RHcyst-1 significantly inhibited the proliferation, migration, and invasion of all four different tumor cells in vitro. Additionally, it inhibited tumor growth and improved survival in vivo. A decrease and an increase in MDSCs levels were observed in PBMCs and in the spleen, respectively, after RHcyst-1 application. Conclusions: Tick RHcyst-1 has potential antitumor efficacy, and the observed antitumor activities may be partly attributable to changes in cathepsin expression and MDSCs levels in the PBMCs and spleens. The findings of the present study suggest that RHcyst-1 may have the potential to be utilized in cancer treatment.
Introduction
Cancer is a major disease with a high mortality rate. Although numerous drugs and treatments have been reported, anticancer therapy remains insufficient. Therefore, there is a need to identify novel treatment regimens to circumvent certain negative features of current anticancer drugs, including poor efficacy and side effects [1] . Proteinases play a major role in immune regulation, inflammation, angiogenesis, apoptosis, and cell-cell communication.
Proteinases have been reported to promote cancer progression and metastasis [2, 3] . Cathepsins, such as cathepsins B, H, K, and L, belong to the family of cysteine proteases that have been associated with cancer progression, tumor burden, overall survival, tumor cell proliferation, angiogenesis, and metastasis [4] [5] [6] [7] . Cathepsins are involved in different cancers and exhibit various characteristics and functions [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Serum cathepsin levels can be used as prognostic markers for melanoma [18] . Cathepsins are thus considered as promising targets for cancer therapy.
Inhibitors targeting cathepsin activity or their expression have been developed and used in cancer therapy [19] [20] [21] . Cancer cells could secrete cathepsins into their environment [22] . Inhibitors that block cathepsin activity or decrease the cathepsin level in the peripheral environment can prevent tumor progression and metastasis. The combination of cathepsin inhibitors with chemotherapy and radiation for cancer treatment has been reported [9, 10] . However, cathepsins comprise several subclasses; thus, the use of one cathepsin may not be effective for another cancer type [23] . The development of more effective inhibitors is therefore warranted.
Cystatins are inhibitors that are reversibly tight-binding with cathepsins and legumains. Cystatins are classified into four subgroups, and they are present in almost all organisms including protozoa [24] . As modulators of cathepsins, cystatins are involved in various physiological and pathological processes such as antigen processing and presentation, cytokines expression, tumor cells proliferation, tumor cells apoptosis, and other tumor genesis and process [25] . A novel natural bioactive molecule, named RHcyst-1, identified from Rhipicephalus haemaphysaloides belongs to type 1 cystatins.
Various bioactive molecules such as natural peptides or proteins isolated from honey, snakes, leeches, ticks, and other blood-sucking arthropods have been identified and studied in relation to the treatment and prevention of disease [26] . Hirudin isolated from leeches possesses strong anticoagulation ability and has been used in antithrombotic therapy and in combination with tumor chemotherapy and radiotherapy. Ticks are bloodfeeding ectoparasitic arthropods that produce various bioactive molecules that display both pluripotency and redundancy, particularly proteins present in the saliva and saliva gland [27] . Other studies have described different native and recombinant proteins with antitumor effects. Ixolaris, a protein isolated from Ixodes scapularis showed potential in decreasing primary tumor growth, metastasis, and angiogenesis [28] . The antitumor effect of Amblyomin-X, a serine protease inhibitor derived from Amblyomma cajennense, has also been reported [29] . HLTnI from Haemaphysalis longicornis is a potent angiogenesis inhibitor that may be potentially utilized as a multi-functional agent for the control of cancer and tick-borne diseases [30] . Additionally, these bioactive molecules have low toxicity and immunogenicity in humans and animals and are thus regarded as ideal and potential antitumor drugs [31] . All these studies indicate that tick-derived bioactive molecules have the potential to be employed in cancer therapy.
We previously cloned and identified RHcyst-1 in our laboratory. It has a strong and broad spectrum of cathepsin inhibitory ability [32] . In the present study, we assessed the antitumor ability of RHcyst-1 in several cancer cell lines in vitro and B16-F10 in vivo. Here, we found that tick-derived RHcyst-1 could inhibit the proliferation, migration, and invasion of different tumor cells in vitro as well as suppress tumor growth and improve overall survival in vivo. At the indicated time points, 100 μL of the fresh medium along with 10 μL of a cell counting kit-8 solution (CCK-8, Dojindo) were added to each well, and the cells were incubated for 2 h at 37°C. The absorbance was measured at a wavelength of 450 nm using a microplate reader (Bio-Tek, USA). The IC50 values were calculated based on the log values using GraphPad Prism 6 software.
Cell migration and invasion assays
Cell migration was assessed using wound healing assays, with cultured cells resuspended and seeded into six-well plates. Cells at 90% confluency in six-well plates were manually scratched with a sterile 200-µL plastic pipette tip. After 0 h and 24 h, images of the wound areas under each condition were photographed. The width of the wound area was quantitated using Image-Pro Plus software (IPP).
Cell invasion assays were performed using 24-well Transwell® chambers with 8-µm pore size polycarbonate membrane filters as previously described [35] . Briefly, the upper surface of the filter was precoated with Matrigel® (BD Biosciences, USA). The Matrigel® was dried at 37°C for 1 h and placed at room temperature overnight. Cells (5 × 10 4 ) in 200 µL of serum-free medium were added to the upper chamber, whereas 500 μL of medium containing 10% FBS were added to the lower chamber. Cells were then allowed to migrate for 24 h, and invading cells were stained with 0.1% crystal violet, counted, and photographed under an inverted microscope.
Western blotting
The cells were harvested and lysed in IP buffer for 20 min on ice and centrifuged for 10 min (12, 000 rpm, 4°C). Protein concentrations were quantified using a BCA protein assay kit (Thermo Scientific™, USA). Then, 50 μg of proteins from each sample were electrophoresed in a 12% SDS-PAGE gel and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). The membranes were blocked with 5% nonfat milk for 1 h at 37°C and probed with a mouse polyclonal anti-RHcyst-1 antibody prepared in-house (1:500) and a mouse monoclonal actin antibody (Protech, USA, 1:3, 000) overnight at 4°C, followed by secondary antibody goat anti-mouse IgG (CST, USA, 1:6, 000) for 1 h at 37°C. Band signals were visualized with fresh diaminobenzidine (DAB, Tiangen, China), which was used as a chromogenic substrate for 5 min.
Indirect immunofluorescent assay (IFA)
At various time points after different treatments, the cells were washed three times with PBS, fixed in 4% (w/v) paraformaldehyde in PBS for 15 min at room temperature, and rewashed with PBS. The fixed cells were then permeabilized with 0.1% Triton X-100 for 10 min (room temperature) and then blocked with 3% BSA for 1 h (37°C). Then, the cells were incubated overnight at 4°C with anti-GST antibody (Protech, USA, 1:2, 000), followed by secondary antibody Alexa Fluor-488 goat anti-mouse IgG (Thermo Scientific™, USA, 1:5, 00) for 1 h (37°C). The cells were washed with PBST, stained with 10 mg/mL DAPI (Sigma-Aldrich, USA) and imaged under a fluorescence microscope.
Immunohistochemistry
Tumors and organs were fixed in formalin and embedded in paraffin. The 5μM sections were cut and stained with hematoxylin and eosin (H&E). For immunohistochemical detection of antigens, the sections were incubated with mouse monoclonal antibodies of anti-CD8
+ at 4°C overnight. After washing with PBS three times, the slides were incubated with biotinylated secondary antibodies, and then it was detected using DAB detection kit (DAB, Tiangen, China). The observations and photography of the sections were performed using Nikon microscope (Nikon, ECLIPSE, JAPAN). 
RNA extraction and quantitative real-time PCR (qRT-PCR) experiments
Total RNA was extracted from cells or tissues using TRIzol® (Life Technologies, USA). cDNA was synthesized using Prime Script™ RT Reagent with genomic DNA removal (Takara, Japan) by following the manufacturer's recommendations. RT-PCR was performed using a SYBR Green mix (Takara, Japan) for 40 amplification cycles of 95°C for 5 min, 95°C for 15 s, and 60°C for 1 min. The relative expression levels of the target genes in each sample were evaluated using the 2 -ΔΔCt method. Mouse β-actin, a housekeeping gene, was used as internal control. The qRT-PCR primers used in this study are listed in Table 1 .
Flow cytometry
To characterize and quantify CD4
+ cells, CD8 + T cells, and MDSCs by FACS, the mice were sacrificed and spleen cell suspensions and PBMCs were prepared, washed with PBS, and then resuspended in a staining buffer. The cell suspensions were then incubated with their respective primary antibodies (anti-CD3-FITC, anti-CD4-PerCP-cy5.5, and anti-CD8-PerCP-cy5.5 for the detection of CD3 +
CD4
+ and CD3 + CD8 + T cells, and anti-CD45-FITC, anti-CD11b-PerCP-cy5.5, and anti-Ly6G-PE for the detection of MDSCs, isotype-matched mAbs for control staining) bought from BD Biosciences for 30 min in the dark at 4°C and then washed with staining buffer twice. Finally, the cells were resuspended in 100 μL of staining buffer for flow cytometry analysis (Beckman CytoFLEX, USA). Data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA).
To test the possible toxicity, the apoptosis assay was performed. After 48 h of 72 μM RHcyst-1 treatment, cells were washed twice with cold 1×PBS, resuspended in 100 μl 1×binding buffer at a concentration of 1 × 10 6 cells/ml, and incubated with 5 μl Alexa Fluor® 488 annexin V and 1 μL 100 μg/mL PI working solution. Samples were incubated for 15 min at room temperature in the dark. After the incubation period, samples were added 400 μL 1× binding buffer and kept on ice. 
Statistical analysis
All statistical analyses were performed using GraphPad Prism 6 software. The IC50 values were calculated based on the log values using GraphPad Prism 6 software. Numerical data were expressed as the mean ± SD, and most of the data were analyzed by the Student t test. Cumulative survival time was calculated using the Kaplan-Meier method and analyzed with the log-rank test. In all statistical analysis, * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001.
Results

Expression and purification of RHcyst-1
The open reading frame of the RHcyst-1 gene was successfully subcloned into the vector pGEX-6p-1. The structure of the recombinant RHcyst-1 (rRHcyst-1) is shown in Fig. 1A . The recombinant protein incorporating a GST tag was successfully expressed with an expected size of 37 kDa. After removal of the GST tag, SDS-PAGE analyses demonstrated that about 2 mg RHcyst-1 (11 kDa) was obtained, with a purity of >95%, and LPS was removed using Detoxi-Gel™ endotoxin-removing columns (Fig. 1B) . Western blot analyses demonstrated that the bioactive recombinant RHcyst-1 and purified RHcyst-1 had molecular weights of about 37 kDa and 11kDa, respectively (Fig. 1C) .
RHcyst-1 exhibits high cysteine protease inhibitory activity
To further confirm whether the RHcyst-1 has the same target protease-inhibiting efficiency as rRHcyst-1, purified RHcyst-1 was used to test its inhibitory activity against cysteine cathepsins. The results showed that RHcyst-1 can also effectively inhibit the enzyme activities of cathepsins B, L, and S but not C (Fig. 2) . The IC50s of RHcyst-1 targeting cathepsins B, L, and S were 524.4 nM, 37.03 nM, and 28.04 nM, respectively. 3A and Fig. 3B ). To explore the safety of RHcyst-1, the normal cell lines 293T, Vero and CHO were treated with RHcyst-1 with a concentration of 18 μM and 72 μM. We found there was no significant effect between RHcyst-1 treatment and control group even at the maximum concentration (Fig. 3C ). In addition, we evaluated the toxicity of RHcyst-1 on tumor and normal cells by flow cytometry. According to the data, RHcyst-1 treatment didn't induce apoptosis on tumor and normal cell lines compared with PBS control groups ( Fig. 3D and Fig. 3E ). Next, we calculated the proliferation of four different tumor cells at the minimum effective concentration of 18 μM (under IC50). The results showed that twenty-four hours after RHcyst-1 treatment with a concentration of 18 μM, a significant decrease in proliferation was observed compared with the control in HeLa and B16-F10 cells, and 48 h after treatment with a concentration of 18 μM, cell proliferation was also suppressed in the A549 and SKOV-3 cells (p < 0.05, Fig. 4 ). These results indicate that RHcyst-1 significantly suppressed the proliferation of the four cancer cell lines in vitro.
RHcyst-1 inhibits tumor cells proliferation but not Normal Cells
RHcyst-1 restrained tumor cell migration and invasion in vitro
Cell migration and invasion are critical steps in tumor progression, and we evaluated the effect of RHcyst-1 on tumor migration and invasive ability by wound healing and Transwell® invasion assays. In the wound healing assay, a significant inhibition in migration and invasion was observed in the four cancer cell lines that were treated with RHcyst-1 compared with the negative control. The mean reductions in the migration of A549, HeLa, SKOV-3, and B16-F10 cells were 73.14%, 36.02%, 25.76%, and 51.10%, respectively (p < 0.05, Fig. 5 ). In addition, the mean invasive suppression rates of the A549, HeLa, SKOV-3 and B16-F10 cells were 45.5%, 67.3%, 58.6%, and 49.7%, respectively (p < 0.05, Fig. 6 ). These findings indicate that RHcyst-1 possesses anti-migratory and anti-invasive activities. (Fig. 7A  and 7B ). In addition, IFA was used to determine the expression patterns of RHcyst-1 at different time points using anti-GST McAb, and pcDNA3.1-GST overexpression transfected in B16-F10 cell was used for the 
RHcyst-1 acts on the extracellular environment
To determine specific binding, active uptake, or direct action of RHcyst-1 on the extracellular environment, B16-F10 cells were treated with 18 µM RHcyst-1 for 12 h, 24 h, and 48 h. The cell supernatants and cell lysis solution were obtained at different times, and Western blotting was performed to assess the level of RHcyst-1 expression in the B16-F10 cell supernatants and cell lysis solution. The purified protein RHcyst-1 which is loaded into the gel was used for the positive control. The results showed that RHcyst-1 could be detected only in the cell supernatants but not in the cell lysis solution
RHcyst-1 inhibits tumor progression in vivo
The B16-F10 cell line that was derived from murine melanoma and the B16-F10 mouse melanoma model system have been widely used in numerous studies [36] [37] [38] [39] . To investigate whether the antitumor effect would also occur in vivo, B16-F10 cells were inoculated into the left forelimbs of C57BL/6 mice to establish a tumor therapy model. Approximately 7 days after B16-F10 cell inoculation, the emerging tumors were measured and recorded. A significant decrease in tumor size was observed in the RHcyst-1 treatment group compared with that in the negative control group (p < 0.05, Fig. 8A) , and the survival of the RHcyst-1 intratumor injection group was significantly prolonged relative to the negative control group (p < 0.05, Fig. 8B ). The mean life span of the RHcyst-1 treatment group increased by about 11.76% relative to the negative control group. These data indicate that RHcyst-1 inhibited tumor progression in vivo.
To explore the safety of RHcyst-1 in vivo, the sections of collected organs from different treatment groups including liver, lung and kidney were stained with H&E [40] [41] [42] . The results of H&E showed no differences between RHcyst-1 and vehicle treatment (Fig. 8C) , indicating RHcyst-1 intratumor injection is safe.
RHcyst-1 mediates specific immune response
MDSCs, as well as T cell levels and balance, play important roles in controlling tumor metastasis and progression [43] . In the present study, we investigated whether RHcyst . Each value (n = 5/ group) represents the mean. (C) Sections of the Heart, Liver, Lung and Kidney were stained with H&E (×200), respectively. Scale bar 100 μm. Bars mean SD. * indicates p<0.05, ** represents p<0.01, and *** signifies p <0.001. Cellular Physiology and Biochemistry associated with immune suppression, and these cells infiltrate and accumulate in the peripheral blood of tumor-bearing mice [44] . These results suggest that RHcyst-1 mediated specific antitumor immunity partly by influencing MDSC from both PBMCs and spleens of tumor-bearing mice.
To evaluate whether RHcyst-1 could promote immune cells infiltration to tumor tissue, we analyzed the amount of CD8 + T cells in the tumor tissue from RHcyst-1 and PBS intratumor injected mice, respectively. The number of CD8 + -positive cells in the tumor from RHcyst-1 treatment mice was higher than the control group (Fig. 9C) . These results suggest that the antitumor immunity of RHcyst-1 was at least in part caused by increasing T cell infiltration.
RHcyst-1 affects mRNA expression of cathepsins
The expression and activity of cathepsins is regulated by their natural endogenous inhibitors that belong to the cystatin family. Previous research studies have reported that the imbalance between cathepsins and cystatins play an important role in tumorigenesis [10, 45, 46] . We analyzed the expression of different cathepsins using qRT-PCR in vitro and in vivo. We construct the overexpression plasmid of RHcyst-1 named pcDNA3.1-GFP-RHcyst-1 and pcDNA3.1-GFP for the control. To evaluate the transfection efficiency and the toxicity after transfection, the Western blotting and the apoptosis assay were performed. RHcyst-1 can be tested and highly expressed in RHcyst-1 transfection group by Western blotting (Fig.  10A) . The apoptosis assay showed that overexpression of RHcyst-1 by transfection cannot induce the apopotosis (Fig. 10B) . The cells were harvested after transfection for 48 h and the expression of different cathepsins in vitro was analyzed using qRT-PCR. We found that the relative expression of all four different cathepsins was downregulated in the high RHcyst-1 expression group (pcDNA3.1-GFP-RHcyst-1 transfection) compared with the negative control (pcDNA3.1-GFP transfection) on B16-F10 cell (Fig. 10C) . The tumor tissues of RHcyst-1 intratumor injection and control were collected and the expression of different cathepsins (Fig. 10D) . Therefore, RHcyst-1 affects mRNA expression of different cathepsins in vitro and in vivo. We speculate the imbalance between cathepsins and RHcyst-1 may partly contribute to the antitumor of RHcyst-1, but it need to be further studied in the following research.
Discussion
Studies have shown that cysteine proteases such as cathepsins are related to tumor growth and progression, which are often upregulated during early-and late-stage tumor cell progression. However, cysteine protease inhibitors such as cystatins regulate the expression and activity of cathepsins. The imbalance between cysteine proteases and cystatins may be clinically useful in combatting cancer [11, 47] . Therefore, cystatins could be considered a potential therapeutic strategy for cancer [8] . In the present study, the small bioactive molecule RHcyst-1 from tick belonging to the type 1 cystatin family has been proven to have effective antitumor activity in vitro and in vivo.
To date, approximately 20 tick cystatins, all belonging to family types 1 and 2, have been reported [48] . Their functions include immunomodulatory (host or itself), Borrelia and Anaplasma phagocytophilum infections, and tick feeding, attachment, and hatching. RHcyst-1 is the member of cystatin family isolated in our lab. To the best of our knowledge, this is the first report of a cystatin isolated from Rhipicephalus haemaphysaloides tick that exhibits antitumor activity in vitro and in vivo. This antitumor effect is similar to various other reported native or recombinant cystatins from other species [45, [49] [50] [51] . However, the molecular mechanism underlying the antitumor effect of RHcyst-1 remains unclear. MDSCs are negatively correlated with tumor prognosis and vasculogenesis [52] . Similarly, in the present study, the number of MDSCs from the PBMCs decreased with RHcyst-1 treatment, indicating that MDSCs may have regulated the antitumor mechanism of RHcyst-1. MDSCs accumulate in the spleens of tumor-bearing mice, where they contribute to immunosuppression [53] . However, we also observed that the MDSCs from the spleens were augmented after RHcyst-1 treatment. It is thus possible that a cross-connection exists between MDSCs and tumor immune regulation [54] . How RHcyst-1 mediates and influences antitumor immune responses by regulating MDSCs from the spleens and PBMCs requires further investigation.
In the present study, no significant binding or uptake in tumor cells was detectable by Western blotting and IFA (Fig. 7) . These results revealed that RHcyst-1 exerted an antitumor effect that possibly involves acting on its extracellular environment. Inhibition of the expression and activities of cathepsins B, L, and S that could be released from cells and function in the degradation of components of the extracellular matrix may influence the tumor progression. The intracellular events induced by cystatins are complex. The present study observed alternations in the relative expression of different cathepsins after RHcyst-1 treatment in vitro and in vivo (Fig. 10) . It is thus possible that the antitumor mechanism of RHcyst-1 is associated at least partly with the level of cathepsins; however, additional investigations confirming this activity are warranted. Using mRNA microarray analysis, we recently showed the RHcyst-1 overexpression by transfecting pcDNA3.1-GFP-RHcyst-1 on HeLa cell lines could induce the upregulation or downregulation of many genes that are primarily involved in cell growth, cell adhesion/migration, and apoptosis, such as Rap1, PI3K-Akt, ErbB, and the calcium signaling pathway (data not shown). Further studies are required to identify the molecular targets of RHcyst-1 that results in the inhibition of tumor cells.
Oncolytic virus therapy is currently considered to be a potential anticancer biological treatment regimen because these viruses can specifically replicate in cancer cells and kill them without damaging normal tissues [55] [56] [57] . Our research team is presently conducting oncolytic virus construction.
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